Shield Therapeutics plc (LON:STX – Get Free Report)’s stock price passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 7.52 and traded as low as GBX 6.07. Shield Therapeutics shares last traded at GBX 6.27, with a volume of 2,088,825 shares trading hands.
Shield Therapeutics Price Performance
The company has a quick ratio of 2.16, a current ratio of 0.90 and a debt-to-equity ratio of -199.87. The firm has a market capitalization of £69.31 million, a P/E ratio of -3.24 and a beta of 1.88. The business’s 50 day moving average is GBX 7.52 and its 200-day moving average is GBX 9.10.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Recommended Stories
- Five stocks we like better than Shield Therapeutics
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
